HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

5- (3- ethynylphenylamino)pyrimido(4,5- c)quinoline- 8- carboxylic acid

structure in first source

Also Known As:

CX 5011; CX-5011; CX5011

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - 5-(3-ethynylphenylamino)pyrimido(4,5-c)quinoline-8-carboxylic acid: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - 5-(3-ethynylphenylamino)pyrimido(4,5-c)quinoline-8-carboxylic acid: 2

Experts

1.	Borgo, Christian: 2 articles (11/2020 - 01/2012)
2.	Pinna, Lorenzo A: 2 articles (11/2020 - 01/2012)
3.	D'Amore, Claudio: 1 article (11/2020)
4.	Hirota, Tsuyoshi: 1 article (11/2020)
5.	Itami, Kenichiro: 1 article (11/2020)
6.	Moro, Enrico: 1 article (11/2020)
7.	Salvi, Mauro: 1 article (11/2020)
8.	Donella-Deana, Arianna: 1 article (01/2012)
9.	Girardi, Cristina: 1 article (01/2012)
10.	Miyata, Yoshihiko: 1 article (01/2012)

Related Diseases

1.

Neoplasms (Cancer)

11/01/2020 - "Based on these evidences, CX-5011 is, therefore, proposed as a potential promising compound for cancer therapies for its dual efficacy as an inhibitor of the pro-survival kinase CK2 and inducer of methuosis."
01/01/2012 - "Among the many inhibitors available for this kinase, the recently developed CX-4945 and CX-5011 have proved to be very potent, selective and effective in inducing cell death in tumor cells; CX-4945 has recently entered clinical trials. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	silmitasertib

Related Therapies and Procedures

1.	Therapeutics